COVID-19 – Domainex response to the pandemic
At Domainex, the health, safety and wellbeing of every employee is our number one priority.
-
Our medicinal chemists believe that 'every compound counts' - Dr Trevor Perrior, CSOEvery Compound Counts -
Domainex is committed to the support of exciting and cutting-edge translational researchTranslational Research -
Domainex applies unique technologies to overcome common drug discovery challengesOvercome Challenges -
Domainex is developing an exciting pipeline of drugs that effect epigenetic targetsExciting Pipeline
Current job opportunities
Message from Tom Mander, CEO of Domainex:
We are seeking applications from suitably qualified biologists (protein or assay scientists), chemists (analytical, computational or medicinal) and business developers.
We especially welcome applications from you if you have relevant industry experience, irrespective of your seniority.
These are exciting times to join us as we continue to invest in our people, facilities, R&D and commercial activities to continue the strong growth of our business.
We look forward to hearing from you!
Drug Discovery Services
Domainex is the fastest growing CRO in Europe. By applying our novel proprietary technologies such as CDH and taking a focussed, integrated approach to medicinal chemistry, biochemistry and computational chemistry we can reduce your project timeline by up to 30%.
New technologies
Domainex has launched its new PoLiPa technology, which can purify any GPCR without the need for thermostabilising mutations or detergents by encapsulating it in a polymer along with a small disc of the native cell membrane lipids. PoLiPa-GPCRs are pharmacologically intact and very stable.
Technology
FragmentBuilder: Fragment screening using MicroScale Thermophoresis
Combinatorial Domain Hunting: Protein expression and purification services.
BioassayBuilder: Bioassay services, assay development, HTS and compound testing services.
LeadBuilder: Virtual hit screening platform.